Literature DB >> 22018763

Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression.

Saumil S Patel1, Joseph Jankovic, Ashley J Hood, Cameron B Jeter, Anne B Sereno.   

Abstract

BACKGROUND: Huntington disease (HD) is a genetic, neurodegenerative disorder characterized by chorea, behavioral co-morbidities, cognitive deficits, and eye movement abnormalities. We sought to evaluate whether reflexive and voluntary orienting prove useful as biomarkers of disease severity in HD.
METHODS: Eleven HD subjects were evaluated with the motor subscale of the Unified Huntington Disease Rating Scale (UHDRS) and the Montreal Cognitive Assessment. Using an infrared eye tracker, we also measured latency and error rates of horizontal and vertical saccades using prosaccade and antisaccade eye movement tasks. We calculated simple and age-controlled correlations between eye movement and clinical parameters.
RESULTS: Prosaccade latency correlated with total chorea score. HD patients with greater clinical severity were significantly slower in the prosaccade task. Antisaccade error rate also correlated with UHDRS motor score and total chorea score. HD patients with greater clinical severity as measured by either measure made significantly more errors in the antisaccade task. All these correlations remained significant even when age was taken into account.
CONCLUSIONS: The results of the present age-controlled study show for the first time that both reflexive and voluntary eye motor control in HD patients decrease with increase in disease severity suggesting declines in both motor and cognitive function. Thus, relatively simple eye movement parameters (latency and error rate) obtained from simple tasks (prosaccade and antisaccade) may serve as quantitative biomarkers of sub-cortical and cortical disease severity in HD and could aid in predicting onset, distinguishing subtypes, or evaluating disease progression and novel therapies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018763      PMCID: PMC3254798          DOI: 10.1016/j.jns.2011.09.035

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  45 in total

1.  Reliability of smooth pursuit, fixation, and saccadic eye movements.

Authors:  Ulrich Ettinger; Veena Kumari; Trevor J Crawford; Robert E Davis; Tonmoy Sharma; Philip J Corr
Journal:  Psychophysiology       Date:  2003-07       Impact factor: 4.016

Review 2.  Cognition and the inhibitory control of saccades in schizophrenia and Parkinson's disease.

Authors:  T J Crawford; D Bennett; G Lekwuwa; S Shaunak; J F W Deakin
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

3.  Why are antisaccades slower than prosaccades? A novel finding using a new paradigm.

Authors:  Bettina Olk; Alan Kingstone
Journal:  Neuroreport       Date:  2003-01-20       Impact factor: 1.837

4.  Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease.

Authors:  T M Blekher; R D Yee; S C Kirkwood; A M Hake; J C Stout; M R Weaver; T M Foroud
Journal:  Vision Res       Date:  2004-10       Impact factor: 1.886

Review 5.  Look away: the anti-saccade task and the voluntary control of eye movement.

Authors:  Douglas P Munoz; Stefan Everling
Journal:  Nat Rev Neurosci       Date:  2004-03       Impact factor: 34.870

Review 6.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

7.  Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene.

Authors:  S C Kirkwood; E Siemers; C Bond; P M Conneally; J C Christian; T Foroud
Journal:  Arch Neurol       Date:  2000-07

8.  Hypometric primary saccades and increased variability in visually-guided saccades in Huntington's disease.

Authors:  C T Winograd-Gurvich; N Georgiou-Karistianis; A Evans; L Millist; J L Bradshaw; A Churchyard; E Chiu; O B White
Journal:  Neuropsychologia       Date:  2003       Impact factor: 3.139

9.  Apraxia of eyelid closure in Huntington's disease.

Authors:  R M Bonelli; G Niederwieser
Journal:  J Neural Transm (Vienna)       Date:  2002-02       Impact factor: 3.575

10.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

Authors:  Nancy S Wexler; Judith Lorimer; Julie Porter; Fidela Gomez; Carol Moskowitz; Edith Shackell; Karen Marder; Graciela Penchaszadeh; Simone A Roberts; Javier Gayán; Denise Brocklebank; Stacey S Cherny; Lon R Cardon; Jacqueline Gray; Stephen R Dlouhy; Sandra Wiktorski; Marion E Hodes; P Michael Conneally; Jack B Penney; James Gusella; Jang-Ho Cha; Michael Irizarry; Diana Rosas; Steven Hersch; Zane Hollingsworth; Marcy MacDonald; Anne B Young; J Michael Andresen; David E Housman; Margot Mieja De Young; Ernesto Bonilla; Theresa Stillings; Americo Negrette; S Robert Snodgrass; Maria Dolores Martinez-Jaurrieta; Maria A Ramos-Arroyo; Jacqueline Bickham; Juan Sanchez Ramos; Frederick Marshall; Ira Shoulson; Gustavo J Rey; Andrew Feigin; Norman Arnheim; Amarilis Acevedo-Cruz; Leticia Acosta; Jose Alvir; Kenneth Fischbeck; Leslie M Thompson; Angela Young; Leon Dure; Christopher J O'Brien; Jane Paulsen; Adam Brickman; Denise Krch; Shelley Peery; Penelope Hogarth; Donald S Higgins; Bernhard Landwehrmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

View more
  15 in total

1.  Impact of Huntington's Disease on Mental Rotation Performance in Motor Pre-Symptomatic Individuals.

Authors:  Shahin Nasr; Herminia D Rosas
Journal:  J Huntingtons Dis       Date:  2019

2.  Anti-saccade error rates as a measure of attentional bias in cocaine dependent subjects.

Authors:  Nadeeka R Dias; Joy M Schmitz; Nuvan Rathnayaka; Stuart D Red; Anne B Sereno; F Gerard Moeller; Scott D Lane
Journal:  Behav Brain Res       Date:  2015-07-08       Impact factor: 3.332

Review 3.  Eye movements in patients with neurodegenerative disorders.

Authors:  Tim J Anderson; Michael R MacAskill
Journal:  Nat Rev Neurol       Date:  2013-01-22       Impact factor: 42.937

Review 4.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

5.  Basic and translational neuro-ophthalmology of visually guided saccades: disorders of velocity.

Authors:  Sushant Puri; Aasef G Shaikh
Journal:  Expert Rev Ophthalmol       Date:  2017-11-28

6.  Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT.

Authors:  Ainhi D Ha; Christopher A Beck; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-02-02

Review 7.  Alterations of eye movement control in neurodegenerative movement disorders.

Authors:  Martin Gorges; Elmar H Pinkhardt; Jan Kassubek
Journal:  J Ophthalmol       Date:  2014-05-18       Impact factor: 1.909

Review 8.  The diagnostic value of saccades in movement disorder patients: a practical guide and review.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Janet C Rucker; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2015-10-15

9.  Voluntary saccade inhibition deficits correlate with extended white-matter cortico-basal atrophy in Huntington's disease.

Authors:  Israel Vaca-Palomares; Brian C Coe; Donald C Brien; Aurelio Campos-Romo; Douglas P Munoz; Juan Fernandez-Ruiz
Journal:  Neuroimage Clin       Date:  2017-06-09       Impact factor: 4.881

10.  Slowed Prosaccades and Increased Antisaccade Errors As a Potential Behavioral Biomarker of Multiple System Atrophy.

Authors:  Sarah H Brooks; Eliana M Klier; Stuart D Red; Neeti D Mehta; Saumil S Patel; Alice Z Chuang; Jessika Suescun; Mya C Schiess; Anne B Sereno
Journal:  Front Neurol       Date:  2017-06-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.